Tomasz Sliwinski

Prof. Tomasz Sliwinski

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
PCPiotr Czarny
Piotr Czarny
PWPaulina Wigner
Paulina Wigner
PGPiotr Galecki
Piotr Galecki
TSTomasz Sliwinski
Tomasz Sliwinski

15 August 2013 in Blood
Verified
Journal Article
Open access
PDF file
KCKimberly Cramer-Morales
Kimberly Cramer-Morales
MNMargaret Nieborowska-Skorska
Margaret Nieborowska-Skorska
KSKara Scheibner
Kara Scheibner
MPMichelle Padget
Michelle Padget
DIDavid A. Irvine
David A. Irvine
TSTomasz Skorski
Tomasz Skorski
Key Points: Targeting RAD52 DNA binding domain I by peptide aptamer induces synthetic lethality in BRCA-deficient leukemias. Individual patients with BRCA-deficient leukemias could be identified by genetic and epigenetic profiling.

6 February 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
MCMichal Ceremuga
Michal Ceremuga
MSMaksymilian Stela
Maksymilian Stela
EJEdyta Janik-Karpinska
Edyta Janik-Karpinska
LGLesław Górniak
Lesław Górniak
ESEwelina Synowiec
Ewelina Synowiec
MBMichal Bijak
Michal Bijak
Bee venom is a very complex mixture produced and secreted by the honeybee (Apis mellifera). Melittin is a major component of bee venom that accounts for about 52% of its dry mass. A vast number of studies have been dedicated to the effects of melittin’s regulation of apoptosis and to the factors that induce apoptosis in various types of cancer such as breast, ovarian, prostate, lung. The latest evidence indicates its potential as a therapeutic agent in the treatment of leukaemia. The aim of our present study is to evaluate melittin’s ability to induce apoptosis in leukaemia cell lines of different origin acute lymphoblastic leukaemia (CCRF-CEM) and chronic myelogenous leukaemia (K-562). We demonstrated that melittin strongly reduced cell viability in both leukaemia cell lines but not in physiological peripheral blood mononuclear cells (PMBCs). Subsequent estimated parameters (mitochondrial membrane potential, Annexin V binding and Caspases 3/7 activity) clearly demonstrated that melittin induced apoptosis in leukaemia cells. This is a very important step for research into the development of new potential anti-leukaemia as well as anticancer therapies. Further analyses on the molecular level have been also planned (analysis of proapoptotic genes expression and DNA damages) for our next research project, which will also focus on melittin.

1 December 2007 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
TSTomasz Sliwinski
Tomasz Sliwinski
WRWioletta Rozej
Wioletta Rozej
AMAlina Morawiec-Bajda
Alina Morawiec-Bajda
ZMZbigniew Morawiec
Zbigniew Morawiec
RRRussel Reiter
Russel Reiter
Janusz BlasiakJanusz Blasiak
Janusz Blasiak

1 January 2009 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
DPDariusz Pytel
Dariusz Pytel
TSTomasz Sliwinski
Tomasz Sliwinski
TPTomasz Popławski
Tomasz Popławski
DFDeborah Ferriola
Deborah Ferriola
IMIreneusz Majsterek
Ireneusz Majsterek
Tyrosine kinases (TKs) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth. Constitutive activated TKs stimulate multiple signaling pathways responsible for DNA repair, apoptosis, and cell proliferation. During the last few years, thorough analysis of the mechanism underlying tyrosine kinases activity led to novel cancer therapy using TKs blockers. These drugs are remarkably effective in the treatment of various human tumors including head and neck, gastric, prostate and breast cancer and leukemias. The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia. The introduction of STI571 for the treatment of leukemia in clinical oncology has had a dramatic impact on how this disease is currently managed. Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase. The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava). Herein, we discuss the chemistry, biological activity and clinical potential of new drugs with tyrosine kinase blockers for cancer treatment.

1 July 2005 in Microbiology
Verified
Journal Article
Open access
PDF file
ABAnna Brzostek
Anna Brzostek
TSTomasz Sliwinski
Tomasz Sliwinski
ARAnna Rumijowska-Galewicz
Anna Rumijowska-Galewicz
MKMałgorzata Korycka-Machała
Małgorzata Korycka-Machała
JDJaroslaw Dziadek
Jaroslaw Dziadek
The catabolic potential for sterol degradation of fast-growing mycobacteria is well known. However, no genes or enzymes responsible for the steroid degradation process have been identified as yet in these species. One of the key enzymes required for degradation of the steroid ring structure is 3-ketosteroid Δ1-dehydrogenase (KsdD). The recent annotation of the Mycobacterium smegmatis genome (TIGR database) revealed six KsdD homologues. Targeted disruption of the MSMEG5898 (ksdD-1) gene, but not the MSMEG4855 (ksdD-2) gene, resulted in partial inactivation of the cholesterol degradation pathway and accumulation of the intermediate 4-androstene-3,17-dione. This effect was reversible by the introduction of the wild-type ksdD-1 gene into M. smegmatis ΔksdD-1 or overexpression of ksdD-2. The data indicate that KsdD1 is the main KsdD in M. smegmatis, but that KsdD2 is able to perform the cholesterol degradation process when overproduced.